Check Point

Checkpoint Therapeutics is a clinical-stage immunotherapy biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead candidate is cosibelimab, a high-affinity, fully human IgG1 monoclonal antibody that directly binds to PD-L1 and inhibits its interaction with PD-1 and B7.1 receptors. Beyond cosibelimab, Checkpoint is developing olmutinib, a third-generation EGFR inhibitor for the treatment of EGFR mutation-positive non-small cell lung cancer. The company aims to provide potentially best-in-class or first-in-class therapies at a more affordable price point than existing immunotherapies. Checkpoint Therapeutics is a majority-owned subsidiary of Fortress Biotech.